Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Assets: 2019-2024

Historic Assets for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to $978.0 million.

  • Kymera Therapeutics' Assets rose 6.49% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 6.49%. This contributed to the annual value of $978.0 million for FY2024, which is 69.87% up from last year.
  • Per Kymera Therapeutics' latest filing, its Assets stood at $978.0 million for FY2024, which was up 69.87% from $575.8 million recorded in FY2023.
  • Over the past 5 years, Kymera Therapeutics' Assets peaked at $978.0 million during FY2024, and registered a low of $487.2 million during FY2020.
  • For the 3-year period, Kymera Therapeutics' Assets averaged around $719.0 million, with its median value being $603.1 million (2022).
  • Per our database at Business Quant, Kymera Therapeutics' Assets skyrocketed by 317.45% in 2020 and then dropped by 4.54% in 2023.
  • Over the past 5 years, Kymera Therapeutics' Assets (Yearly) stood at $487.2 million in 2020, then grew by 24.37% to $605.9 million in 2021, then declined by 0.46% to $603.1 million in 2022, then decreased by 4.54% to $575.8 million in 2023, then soared by 69.87% to $978.0 million in 2024.